Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Accumulated Expenses (2016 - 2025)

AC Immune (ACIU) has disclosed Accumulated Expenses for 9 consecutive years, with $13.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses rose 10.49% to $13.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $13.8 million, a 10.49% increase, with the full-year FY2024 number at $13.8 million, up 11.87% from a year prior.
  • Accumulated Expenses was $13.8 million for Q4 2024 at AC Immune, up from $12.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $18.2 million in Q4 2021 to a low of $9.8 million in Q4 2022.
  • A 5-year average of $13.3 million and a median of $12.5 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 319.05% in 2020, then crashed 46.14% in 2022.
  • AC Immune's Accumulated Expenses stood at $12.3 million in 2020, then surged by 48.02% to $18.2 million in 2021, then plummeted by 46.14% to $9.8 million in 2022, then increased by 27.87% to $12.5 million in 2023, then increased by 10.49% to $13.8 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Accumulated Expenses are $13.8 million (Q4 2024), $12.5 million (Q4 2023), and $9.8 million (Q4 2022).